MedTrace Logo

A Randomized Controlled Test of the Effects of CHI-554 on Fear.

NCT04577612 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2021-06-03

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled phase 2b clinical trial examining the effects of CHI-554 (CBD) on Fear (F-01)

Conditions

Interventions

DRUG

CHI-554

hemp-derived CBD in MCT oil

Sponsors & Collaborators

  • University of Arkansas

    collaborator OTHER

  • Canopy Growth Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2021-05-15
Completion
2021-05-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04577612 on ClinicalTrials.gov